– UK, London – Advanced Oncotherapy (AIM: AVO) is pleased to announce the appointment of Sanjeev Pandya, the Company’s acting Chief Operating Officer, as an Executive Director and permanent Chief Operating Officer, with immediate effect.
Sanjeev Pandya, aged 45, trained and practised as an orthopaedic surgeon in the NHS in the UK and in developing countries before working as a strategy consultant with McKinsey & Company. He then spent two years at Pfizer Global Pharmaceuticals division before joining Lehman Brothers as an investment banker in healthcare M&A. More recently, he has worked as an independent consultant in Russia and at Bupa in London. He is a director of Odin Healthcare Limited. He has a medical degree from Trinity College, Cambridge and an MBA from INSEAD.
Advanced Oncotherapy’s Chairman, Lord Evans of Watford, said, “We are pleased that Sanjeev has accepted our invitation to become our permanent Chief Operating Officer and to join the Board. Sanjeev has clearly spent some time getting to know the Company, the team and the technology and I am delighted to welcome him to the Board after this process. Sanjeev’s background and commercial experience will add great value to the executive team that he leads as we translate our technology into real world commercial success.”
Commenting on his appointment, Sanjeev Pandya said, “I am delighted to be given this opportunity at such an exciting time for the Company. We continue to make strides in all parts of our business from manufacturing to expanding our team of world-renowned advisors and leading experts in their respective fields of business. I am confident that this technology will revolutionise the fight against cancer.”
About Advanced Oncotherapy Plc
AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.
AVO’s acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of proprietary radiotherapy equipment called LIGHT. This patented technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.
AVO’s subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK through BMI, Spire and other hospitals.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.